Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.

about

Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions.Categorization and association analysis of risk factors for adverse drug events.Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience.

P2860

Q40599927-3E58679D-A4D3-419F-9CC2-1B682B68B021 Q47339342-128B27E9-DAF6-477D-93B6-3086189E1ABC Q48110717-8128EE4E-7C2B-4E35-A0BB-5D5D0CDBBEF1

P2860

Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.

Item

http://www.wikidata.org/entity/Q41056478

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Prevalence and detection of ne ...... during hepatitis C treatment.

@en

type

Item

label

Prevalence and detection of ne ...... during hepatitis C treatment.

@en

prefLabel

Prevalence and detection of ne ...... during hepatitis C treatment.

@en

P1476

Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment

@en

P2093

Adolfo Gallego

http://www.w3.org/2001/XMLSchema#string

Laura Tuneu

http://www.w3.org/2001/XMLSchema#string

Maria Antònia Mangues

http://www.w3.org/2001/XMLSchema#string

María José Faus

http://www.w3.org/2001/XMLSchema#string

Montserrat Masip

http://www.w3.org/2001/XMLSchema#string

Neus Pagès

http://www.w3.org/2001/XMLSchema#string

Xavier Torras

http://www.w3.org/2001/XMLSchema#string

P2860

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

A method for estimating the probability of adverse drug reactions

Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.

Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis.

Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.

P2888

s11096-015-0177-1

P304

1143-1151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11096-015-0177-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Guardiola

P577

2015-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26267215

http://www.w3.org/2001/XMLSchema#string

Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.

about

P2860

P2860

Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698